- Home
- BIT vs CSTL Comparison
BIT vs CSTL Comparison
Compare BIT & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIT
- CSTL
- Stock Information
- Founded
- BIT 2013
- CSTL 2007
- Country
- BIT United States
- CSTL United States
- Employees
- BIT N/A
- CSTL N/A
- Industry
- BIT Trusts Except Educational Religious and Charitable
- CSTL Medical Specialities
- Sector
- BIT Finance
- CSTL Health Care
- Exchange
- BIT Nasdaq
- CSTL Nasdaq
- Market Cap
- BIT 616.7M
- CSTL 697.9M
- IPO Year
- BIT N/A
- CSTL 2019
- Fundamental
- Price
- BIT $13.82
- CSTL $21.64
- Analyst Decision
- BIT
- CSTL Strong Buy
- Analyst Count
- BIT 0
- CSTL 6
- Target Price
- BIT N/A
- CSTL $37.67
- AVG Volume (30 Days)
- BIT 92.4K
- CSTL 461.9K
- Earning Date
- BIT 01-01-0001
- CSTL 11-03-2025
- Dividend Yield
- BIT 9.36%
- CSTL N/A
- EPS Growth
- BIT N/A
- CSTL N/A
- EPS
- BIT N/A
- CSTL N/A
- Revenue
- BIT N/A
- CSTL $346,269,000.00
- Revenue This Year
- BIT N/A
- CSTL N/A
- Revenue Next Year
- BIT N/A
- CSTL N/A
- P/E Ratio
- BIT N/A
- CSTL N/A
- Revenue Growth
- BIT N/A
- CSTL 20.40
- 52 Week Low
- BIT $13.65
- CSTL $14.59
- 52 Week High
- BIT $15.97
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- BIT 43.02
- CSTL 49.89
- Support Level
- BIT $13.62
- CSTL $22.54
- Resistance Level
- BIT $13.99
- CSTL $24.74
- Average True Range (ATR)
- BIT 0.15
- CSTL 1.12
- MACD
- BIT 0.05
- CSTL -0.18
- Stochastic Oscillator
- BIT 69.49
- CSTL 28.02
About BIT BlackRock Multi-Sector Income Trust of Beneficial Interest
BlackRock Multi-Sector Income Trust is a closed-end investment management company. It invests on behalf of its clients. The fund's primary investment objective is to provide a high level of current income, with a secondary objective of capital appreciation. The company seeks to achieve its investment objectives by investing, under normal market conditions, a majority of its assets in loan and debt instruments and other investments with similar economic characteristics. Its portfolio consists of Corporate Bonds, Asset-Backed Securities, Preferred Securities, and others.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.